Analysts have been eager to weigh in on the Technology sector with new ratings on OptimizeRx (OPRX – Research Report), Desktop Metal (DM – Research Report) and Stratasys (SSYS – Research Report).
OptimizeRx (OPRX)
In a report released yesterday, Eric Martinuzzi from Lake Street reiterated a Buy rating on OptimizeRx, with a price target of $18.00. The company’s shares closed last Thursday at $13.61, close to its 52-week low of $11.59.
According to TipRanks.com, Martinuzzi is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for OptimizeRx with a $21.50 average price target, representing a 59.2% upside. In a report issued on May 10, SVB Securities also reiterated a Buy rating on the stock with a $18.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Desktop Metal (DM)
In a report released today, Greg Palm from Craig-Hallum maintained a Hold rating on Desktop Metal. The company’s shares closed last Thursday at $2.02.
According to TipRanks.com, Palm is a 4-star analyst with an average return of
Currently, the analyst consensus on Desktop Metal is a Hold with an average price target of $2.13, a 21.7% upside from current levels. In a report issued on May 11, Credit Suisse also maintained a Hold rating on the stock with a $2.00 price target.
Stratasys (SSYS)
In a report released today, Troy Jensen from Lake Street maintained a Buy rating on Stratasys, with a price target of $21.00. The company’s shares closed last Thursday at $15.94.
According to TipRanks.com, Jensen is a 5-star analyst with an average return of
Currently, the analyst consensus on Stratasys is a Strong Buy with an average price target of $15.86, a 6.6% upside from current levels. In a report issued on May 17, Craig-Hallum also reiterated a Buy rating on the stock with a price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OPRX:
- OptimizeRx’s CEO Provides 2023 Midyear Strategic Update
- Down More Than 50%: These 3 Beaten-Down Stocks Could Stage a Strong Rebound, Analysts Say
- OptimizeRx’s Karina Castagna Named One of the 2023 PM360 ELITE 100
- OptimizeRx Reports First Quarter 2023 Financial Results
- OPRX Earnings this Week: How Will it Perform?
